Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

Arthritis Care and Research

Volumn 62, Issue 8, 2010, Pages 1166-1173

  Walsh, Michael ^a,b   Merkel, Peter A ^c   Mahr, Alfred ^c   Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; EFFECT MODIFIERS (EPIDEMIOLOGY); FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; TREATMENT OUTCOME; VASCULITIS;

EID: 77955236779     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20176     Document Type: Article

References (37)

1. Collagen Diseases and Hypersensitivity Panel (MRC). Treatment of polyarteritis nodosa with cortisone: results after three years. Br Med J 1960;1:1399-1400.
2. Frohnert PF, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967;43:8-11.
3. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971;285:1493-6.
4. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971;284:938-42.
5. Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979;67:941-5.
6. Nachman PH, Hogan SL, Jennette JC, Falk RJ, Nachman PH, Hogan SL, et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9.
7. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
8. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403-10.
9. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-9.
10. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
11. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
12. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
13. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
14. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
15. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
16. OMERACT 7. Proceedings of the International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. 2004 May 8-12. Asilomar, California. J Rheumatol 2005;32:2447-95.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
18. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
20. Frost C, Clarke R, Beacon H. Use of hierarchical models for meta-analysis: experience in the metabolic ward studies of diet and blood cholesterol. Stat Med 1999;18:1657-76.
21. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865-84.
22. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004;140:589-602.
23. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
24. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al, and the French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93-100.
25. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
26. De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/ sulfarnethoxazole. Arthritis Rheum 1996;39:2052-61.
27. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326-32.
28. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.
29. De Groot K, Jayne D, Tesar V, Savage C. Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis [abstract]. Kidney Blood Pres Res 2005;28:195.
30. Metzler C, Wagner-Bastmeyer R, Gross WL, Reinhold-Keller E. Leflunomide versus methotrexate for maintenance of remission in Wegener's granulomatosis: unexpected high relapse-rate under oral methotrexate [abstract]. Ann Rheum Dis 2005;64 Suppl 3:262.
31. Pagnoux C, Mahr A, Cohen P, Hamidou M, Ruivard M, Puechal X, et al. Corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (WEGENT) [abstract]. Ann Rheum Dis 2005;64 Suppl 3:246.
32. Metzler C, Miehle N, Manger K, Iking-Konert C, De Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1087-91.
33. De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
34. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
35. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-73.
36. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836-40.
37. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.